

1. Swerdlow SH, Campo E, Harris NL, et al., eds. *WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues*. Lyon: International Agency for Research on Cancer; 2008.
2. Jung D, Giallourakis C, Mostoslavsky R, et al. Mechanism and control of V(D)J recombination at the immunoglobulin heavy chain locus. *Annu Rev Immunol* 2006;24:541–570.
3. Rajewsky K. Clonal selection and learning in the antibody system. *Nature* 1996;381:751–758.
4. Klein U, Dalla-Favera R. Germinal centres: role in B-cell physiology and malignancy. *Nat Rev Immunol* 2008;8:22–33.
5. MacLennan IC. Germinal centers. *Annu Rev Immunol* 1994;12:117–139.
6. Green JA, Cyster JG. S1PR2 links germinal center confinement and growth regulation. *Immunity* 2012;24:7:36–51.
7. Allen CD, Okada T, Tang HL, et al. Imaging of germinal center selection events during affinity maturation. *Science* 2007;315:528–531.
8. Schwickert TA, Lindquist RL, Shakhar G, et al. In vivo imaging of germinal centers reveals a dynamic open structure. *Nature* 2007;446:83–87.
9. Victora GD, Schwickert TA, Fooksman DR, et al. Germinal center dynamics revealed by multiphoton microscopy with a photoactivatable fluorescent reporter. *Cell* 2010;143:592–605.
10. Di Noia JM, Neuberger MS. Molecular mechanisms of antibody somatic hypermutation. *Annu Rev Biochem* 2007;76:1–22.
11. Goossens T, Klein U, Küppers R. Frequent occurrence of deletions and duplications during somatic hypermutation: implications for oncogene translocations and heavy chain disease. *Proc Natl Acad Sci U S A* 1998;95:2463–2468.
12. Küppers R, Zhao M, Hansmann ML, et al. Tracing B cell development in human germinal centres by molecular analysis of single cells picked from histological sections. *EMBO J* 1993;12:4955–4967.
13. Klein U, Tu Y, Stolovitzky GA, et al. Transcriptional analysis of the B cell germinal center reaction. *Proc Natl Acad Sci U S A* 2003;100:2639–2644.
14. Cattoretti G, Ghang CC, Cechova K, et al. BCL-6 protein is expressed in germinal-center B cells. *Blood* 1995;86:45–53.
15. Chang CC, Ye BH, Chaganti RS, et al. BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor. *Proc Natl Acad Sci U S A* 1996;93:6947–6952.
16. Basso K, Saito M, Sumazin P, et al. Integrated biochemical and computational approach identifies BCL6 direct target genes controlling multiple pathways in normal germinal center B cells. *Blood* 2010;115:975–984.
17. Niu H, Cattoretti G, Dalla-Favera R. BCL6 controls the expression of the B7-1/CD80 costimulatory receptor in germinal center B cells. *J Exp Med* 2003;198:211–221.
18. Ci W, Polo JM, Cerchiotti L, et al. The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. *Blood* 2009;113:5536–5548.
19. Phan RT, Dalla-Favera R. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. *Nature* 2004;432:635–639.
20. Phan RT, Saito M, Basso K, et al. BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells. *Nat Immunol* 2005;6:1054–1060.
21. Ranuncolo SM, Polo JM, Dierov J, et al. Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. *Nat Immunol* 2007;8:705–714.
22. Ranuncolo SM, Polo JM, Melnick A. BCL6 represses CHEK1 and suppresses DNA damage pathways in normal and malignant B-cells. *Blood Cells Mol Dis* 2008;41:95–99.
23. Keller AD, Maniatis T. Identification and characterization of a novel repressor of beta-interferon gene expression. *Genes Dev* 1991;5:868–879.
24. Turner CA Jr, Mack DH, Davis MM. Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells. *Cell* 1994;77:297–306.
25. Shaffer AL, Yu X, He Y, et al. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. *Immunity* 2000;13:199–212.
26. Tunyaplin C, Shaffer AL, Angelin-Duclos CD, et al. Direct repression of prdm1 by Bcl-6 inhibits plasmacytic differentiation. *J Immunol* 2004;173:1158–1165.
27. Honjo T, Kinoshita K, Muramatsu M. Molecular mechanism of class switch recombination: linkage with somatic hypermutation. *Annu Rev Immunol* 2002;20:165–196.
28. Longrich S, Basu U, Alt F, et al. AID in somatic hypermutation and class switch recombination. *Curr Opin Immunol* 2006;18:164–174.
29. Muramatsu M, Kinoshita K, Fagarasan S, et al. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. *Cell* 2000;102:553–563.
30. Revy P, Muto T, Levy Y, et al. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). *Cell* 2000;102:565–575.
31. Küppers R, Klein U, Hansmann ML, et al. Cellular origin of human B-cell lymphomas. *N Engl J Med* 1999;341:1520–1529.
32. Nussenzweig A, Nussenzweig MC. Origin of chromosomal translocations in lymphoid cancer. *Cell* 2010;141:27–38.
33. von Boehmer H, Aifantis I, Gounari F, et al. Thymic selection revisited: how essential is it? *Immunol Rev* 2003;191:62–78.
34. Küppers R, Dalla-Favera R. Mechanisms of chromosomal translocations in B cell lymphomas. *Oncogene* 2001;20:5580–5594.
35. Tsujimoto Y, Gorham J, Cossman J, et al. The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. *Science* 1985;229:1390–1393.
36. Tsujimoto Y, Louie E, Bashir MM, et al. The reciprocal partners of both the t(14; 18) and the t(11; 14) translocations involved in B-cell neoplasms are rearranged by the same mechanism. *Oncogene* 1988;2:347–351.
37. Ramiro AR, Jankovic M, Eisenreich T, et al. AID is required for c-myc/IgH chromosome translocations in vivo. *Cell* 2004;118:431–438.
38. Robbiani DF, Bothmer A, Callen E, et al. AID is required for the chromosomal breaks in c-myc that lead to c-myc/IgH translocations. *Cell* 2008;135:1028–1038.
39. Pasqualucci L, Bhagat G, Jankovic M, et al. AID is required for germinal center-derived lymphomagenesis. *Nat Genet* 2008;40:108–112.
40. Akasaka H, Akasaka T, Kurata M, et al. Molecular anatomy of BCL6 translocations revealed by long-distance polymerase chain reaction-based assays. *Cancer Res* 2000;60:2335–2341.
41. Chen W, Iida S, Louie DC, et al. Heterologous promoters fused to BCL6 by chromosomal translocations affecting band 3q27 cause its deregulated expression during B-cell differentiation. *Blood* 1998;91:603–607.
42. Ye BH, Lista F, Lo Coco F, et al. Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. *Science* 1993;262:747–750.
43. Ye BH, Rao PH, Chaganti RS, et al. Cloning of bcl-6, the locus involved in chromosome translocations affecting band 3q27 in B-cell lymphoma. *Cancer Res* 1993;53:2732–2735.
44. Yoshida S, Kaneita Y, Aoki Y, et al. Identification of heterologous translocation partner genes fused to the BCL6 gene in diffuse large B-cell lymphomas: 5'-RACE and LA-PCR analyses of biopsy samples. *Oncogene* 1999;18:7994–7999.
45. Baron BW, Nucifora G, McCabe N, et al. Identification of the gene associated with the recurring chromosomal translocations t(3;14)(q27;q32) and t(3;22)(q27;q11) in B-cell lymphomas. *Proc Natl Acad Sci U S A* 1993;90:5262–5266.
46. Kerckaert JP, Dewindt C, Tilly H, et al. LAZ3, a novel zinc-finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphomas. *Nat Genet* 1993;5:66–70.
47. Miki T, Kawamata N, Aria A, et al. Molecular cloning of the breakpoint for 3q27 translocation in B-cell lymphomas and leukemias. *Blood* 1994;83:217–222.
48. Pasqualucci L, Neumeister P, Goossens T, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. *Nature* 2001;412:341–346.
49. Neuberger MS. Antibody diversification by somatic mutation: from Burnet onwards. *Immunol Cell Biol* 2008;86:124–132.
50. Gordon MS, Kanegai CM, Doerr JR, et al. Somatic hypermutation of the B cell receptor genes B29 (Igbeta, CD79b) and mb1 (Igalpha, CD79a). *Proc Natl Acad Sci U S A* 2003;100:4126–4131.
51. Mischen M, Re D, Jungnickel B, et al. Somatic mutation of the CD95 gene in human B cells as a side-effect of the germinal center reaction. *J Exp Med* 2000;192:1833–1840.
52. Pasqualucci L, Migliazza A, Fracchiolla N, et al. BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci. *Proc Natl Acad Sci U S A* 1998;95:11816–11821.
53. Shen HM, Peters A, Baron B, et al. Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes. *Science* 1998;280:1750–1752.
54. Cerri M, Capello D, Muti G, et al. Aberrant somatic hypermutation in post-transplant lymphoproliferative disorders. *Br J Haematol* 2004;127:362–364.
55. Deusch AJ, Aigelsreiter A, Staber PB, et al. MALT lymphoma and extranodal diffuse large B-cell lymphoma are targeted by aberrant somatic hypermutation. *Blood* 2007;109:3500–3504.
56. Gaidano G, Pasqualucci L, Capello D, et al. Aberrant somatic hypermutation in multiple subtypes of AIDS-associated non-Hodgkin lymphoma. *Blood* 2003;102:1833–1841.
57. Montesinos-Rongen M, Van Roost D, Schaller C, et al. Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation. *Blood* 2004;103:1869–1875.
58. Vakiani E, Basso K, Klein U, et al. Genetic and phenotypic analysis of B-cell post-transplant lymphoproliferative disorders provides insights into disease biology. *Hematol Oncol* 2008;26:199–211.
59. Storb U, Peters A, Klotz E, et al. Cis-acting sequences that affect somatic hypermutation of Ig genes. *Immunol Rev* 1998;162:153–160.
60. Houldsworth J, Mathew S, Rao PH, et al. REL proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma. *Blood* 1996;87:25–29.
61. Houldsworth J, Oishen AB, Cattoretti G, et al. Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B-cell lymphomas. *Blood* 2004;103:1862–1868.
62. Rao PH, Houldsworth J, Dyomina K, et al. Chromosomal and gene amplification in diffuse large B-cell lymphoma. *Blood* 1998;92:234–240.

63. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. *N Engl J Med* 2002;346:1937–1947.
64. Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. *Blood* 2010;116:3268–3277.
65. Rui L, Emre NC, Krulhak MJ, et al. Cooperative epigenetic modulation by cancer amplicon genes. *Cancer Cell* 2010;18:590–605.
66. Neri A, Knowles DM, Greco A, et al. Analysis of RAS oncogene mutations in human lymphoid malignancies. *Proc Natl Acad Sci U S A* 1988;85:9268–9272.
67. Hollstein M, Sidransky D, Vogelstein B, et al. p53 mutations in human cancers. *Science* 1991;253:49–53.
68. Gaidano G, Ballerini P, Gong JZ, et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. *Proc Natl Acad Sci U S A* 1991;88:5413–5417.
69. Lo Coco F, Gaidano G, Louie DC, et al. p53 mutations are associated with histologic transformation of follicular lymphoma. *Blood* 1993;82:2289–2295.
70. Gaidano G, Gaupthein RS, Parsa NZ, et al. Deletions involving two distinct regions of 6q in B-cell non-Hodgkin lymphoma. *Blood* 1992;80:1781–1787.
71. Offit K, Wong G, Filippa DA, et al. Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin's lymphoma: clinical correlations. *Blood* 1991;77:1508–1515.
72. Mandelbaum J, Bhagat G, Tang H, et al. BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. *Cancer Cell* 2010;18:568–579.
73. Pasqualucci L, Compagno M, Houldsworth J, et al. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. *J Exp Med* 2006;203:311–317.
74. Tam W, Gomez M, Chadburn A, et al. Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas. *Blood* 2006;107:4090–4100.
75. Compagno M, Lim WK, Grunn A, et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. *Nature* 2009;459:717–721.
76. Kato M, Sanada M, Kato I, et al. Frequent inactivation of A20 in B-cell lymphomas. *Nature* 2009;459:712–716.
77. Novak U, Rinaldi A, Kwee I, et al. The NF-(kappa)B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. *Blood* 2009;113:4918–4921.
78. Schmitz R, Hansmann ML, Bohle V, et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. *J Exp Med* 2009;206:981–989.
79. Pasqualucci L, Dominguez-Sola D, Chiarenza A, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. *Nature* 2011;471:189–195.
80. Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. *Nature* 2011;476:298–303.
81. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. *N Engl J Med* 2000;343:1910–1916.
82. Fabbri G, Khiabanian H, Holmes AB, et al. Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome. *J Exp Med* 2013;210:2273–2288.
83. Lenz G, Wright GW, Emre NC, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. *Proc Natl Acad Sci U S A* 2008;105:13520–13525.
84. Pasqualucci L, Khiabanian H, Fangazio M, et al. Genetics of follicular lymphoma transformation. *Cell Rep* 2014;6:130–140.
85. Martinez-Delgado B, Robledo M, Arranz E, et al. Hypermethylation of p15/ink4b/MTS2 gene is differentially implicated among non-Hodgkin's lymphomas. *Leukemia* 1998;12:937–941.
86. zur Hausen H, Schulte-Holthausen H, Klein G, et al. EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. *Nature* 1970;228:1056–1058.
87. Magrath IT. African Burkitt's lymphoma. History, biology, clinical features, and treatment. *Am J Pediatr Hematol Oncol* 1991;13:222–246.
88. Neri A, Barriga F, Inghirami G, et al. Epstein-Barr virus infection precedes clonal expansion in Burkitt's and acquired immunodeficiency syndrome-associated lymphoma. *Blood* 1991;77:1092–1095.
89. Ballerini P, Gaidano G, Gong JZ, et al. Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. *Blood* 1993;81:166–176.
90. Horenstein MG, Nador RG, Chadburn A, et al. Epstein-Barr virus latent gene expression in primary effusion lymphomas containing Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8. *Blood* 1997;90:1186–1191.
91. Cingolani A, Castaldi R, Fassone L, et al. Epstein-Barr virus infection is predictive of CNS involvement in systemic AIDS-related non-Hodgkin's lymphomas. *J Clin Oncol* 2000;18:3325–3330.
92. Fassone L, Bhatia K, Gutierrez M, et al. Molecular profile of Epstein-Barr virus infection in HHV-8-positive primary effusion lymphoma. *Leukemia* 2000;14:271–277.
93. Kieff E, Leibowitz D. Oncogenesis by herpesvirus. In: Weinberg RA, ed. *Oncogenes and the Molecular Origin of Cancer*. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1989: 259.
94. Raab-Traub N, Flynn K. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. *Cell* 1986;47:883–889.
95. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. *Science* 1994;266:1865–1869.
96. Soulier J, Grollet L, Oksenhelder E, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castlemans disease. *Blood* 1995;86:1276–1280.
97. Cesarman E, Chang Y, Moore PS, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. *N Engl J Med* 1995;332:1186–1191.
98. Gaidano G, Pastore C, Gloghini A, et al. Distribution of human herpesvirus-8 sequences throughout the spectrum of AIDS-related neoplasia. *Aids* 1996;10:941–949.
99. Moore PS, Gao SJ, Dominguez G, et al. Primary characterization of a herpesvirus agent associated with Kaposi's sarcoma. *J Virol* 1996;70:549–558.
100. Poiesz BJ, Russett FW, Gazdar AF, et al. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. *Proc Natl Acad Sci U S A* 1980;77:7415–7419.
101. Ferreira OC Jr, Planelles V, Rosenblatt JD. Human T-cell leukemia viruses: epidemiology, biology, and pathogenesis. *Blood Rev* 1997;11:91–104.
102. Uchiyama T. Human T cell leukemia virus type I (HTLV-I) and human diseases. *Annu Rev Immunol* 1997;15:15–37.
103. Yoshida M. Howard Temin Memorial Lectureship. Molecular biology of HTLV-1: deregulation of host cell gene expression and cell cycle. *Leukemia* 1997;11:1–2.
104. Cross SL, Feinberg MB, Wolf JB, et al. Regulation of the human interleukin-2 receptor alpha chain promoter: activation of a nonfunctional promoter by the transactivator gene of HTLV-I. *Cell* 1987;49:47–56.
105. Fujii M, Sassone-Corsi P, Verma IM. c-fos promoter trans-activation by the tax1 protein of human T-cell leukemia virus type I. *Proc Natl Acad Sci U S A* 1988;85:8526–8530.
106. Inoue J, Seiki M, Taniguchi T, et al. Induction of interleukin 2 receptor gene expression by p40x encoded by human T-cell leukemia virus type 1. *Embo J* 1986;5:2883–2888.
107. Nimer SD, Gasson JC, Hu K, et al. Activation of the GM-CSF promoter by HTLV-I and -II tax proteins. *Oncogene* 1989;4:671–676.
108. Wano Y, Feinberg M, Hosking JB, et al. Stable expression of the tax gene of type I human T-cell leukemia virus in human T cells activates specific cellular genes involved in growth. *Proc Natl Acad Sci U S A* 1988;85:9733–9737.
109. Jeang KT, Widen SG, Semmes OJ 4th, et al. HTLV-I trans-activator protein, tax, is a trans-repressor of the human beta-polymerase gene. *Science* 1990;247:1082–1084.
110. Jin DY, Spencer F, Jeang KT. Human T cell leukemia virus type 1 oncoprotein Tax targets the human mitotic checkpoint protein MAD1. *Cell* 1998;93:81–91.
111. Marcucci F, Mele A. Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities. *Blood* 2011;117:1792–1798.
112. Hermine O, Lefrere F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. *N Engl J Med* 2002;347:89–94.
113. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, et al. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. *Lancet* 1991;338:1175–1176.
114. Dogliani C, Wotherspoon AC, Moschini A, et al. High incidence of primary gastric lymphoma in northeastern Italy. *Lancet* 1992;339:834–835.
115. Parsonnet J, Hansen S, Rodriguez L, et al. Helicobacter pylori infection and gastric lymphoma. *N Engl J Med* 1994;330:1267–1271.
116. Wotherspoon AC, Dogliani C, Diss TC, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. *Lancet* 1993;342:575–577.
117. Liu H, Ruskon-Fourmestreaux A, Lavergne-Slove A, et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. *Lancet* 2001;357:39–40.
118. Ferreri AJ, Dolcetti R, Magnino S, et al. Chlamydia infection: the link with ocular adnexal lymphomas. *Nat Rev Clin Oncol* 2009;6:658–669.
119. Stefanovic A, Lossos IS. Extranodal marginal zone lymphoma of the ocular adnexa. *Blood* 2009;114:501–510.
120. Ferreri AJ, Ponzoni M, Guidoboni M, et al. Regression of ocular adnexal lymphoma after Chlamydia pситtaci-eradicating antibiotic therapy. *J Clin Oncol* 2005;23:5067–5073.
121. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. *Nat Rev Cancer* 2007;7:750–762.
122. Tsujimoto Y, Jaffe E, Cossman J, et al. Clustering of breakpoints on chromosome 11 in human B-cell neoplasms with the t(11;14) chromosome translocation. *Nature* 1985;315:340–343.
123. Tsujimoto Y, Yunis J, Onorato-Showe L, et al. Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation. *Science* 1984;224:1403–1406.
124. Erikson J, Finan J, Tsujimoto Y, et al. The chromosome 14 breakpoint in neoplastic B cells with the t(11;14) translocation involves the immunoglobulin heavy chain locus. *Proc Natl Acad Sci U S A* 1984;81:4144–4148.

125. Motokura T, Bloom T, Kim HG, et al. A novel cyclin encoded by a bell-linked candidate oncogene. *Nature* 1991;350:512–515.
126. Rosenberg CL, Wong E, Petty EM, et al. PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. *Proc Natl Acad Sci U S A* 1991;88:9638–9642.
127. Withers DA, Harvey RC, Faust JB, et al. Characterization of a candidate bcl-1 gene. *Mol Cell Biol* 1991;11:4846–4853.
128. Seto M, Yamamoto K, Iida S, et al. Gene rearrangement and overexpression of PRAD1 in lymphoid malignancy with t(11;14)(q13;q32) translocation. *Oncogene* 1992;7:1401–1406.
129. Komatsu H, Iida S, Yamamoto K, et al. A variant chromosome translocation at 11q13 identifying PRAD1/cyclin D1 as the BCL-1 gene. *Blood* 1994;84:1226–1231.
130. Wiestner A, Tehrani M, Chiorazzi M, et al. Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. *Blood* 2007;109:4599–4606.
131. Bodrug SE, Warner BJ, Bath ML, et al. Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. *Embo J* 1994;13:2124–2130.
132. Lovce H, Grzeschiczek A, Kowalski MB, Moroy T. Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. *Embo J* 1994;13:3487–3495.
133. Schaffner C, Idler I, Stigenbauer S, et al. Mantle cell lymphoma is characterized by inactivation of the ATM gene. *Proc Natl Acad Sci U S A* 2000;97:2773–2778.
134. Louie DC, Offit K, Jaslow R, et al. p53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11;14)(q13;q32). *Blood* 1995;86:2892–2899.
135. Pinyol M, Hernandez L, Cazorla M, et al. Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. *Blood* 1997;89:272–280.
136. Bea S, Valdes-Mas R, Navarro A, et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. *Proc Natl Acad Sci U S A* 2013;110:18250–1825.
137. Kridel R, Meissner B, Rogic S, et al. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. *Blood* 2012;119:1963–1971.
138. Bea S, Tort F, Pinyol M, et al. BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. *Cancer Res* 2001;61:2409–2412.
139. Bea S, Salaverria I, Armengol L, et al. Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling. *Blood* 2009;113:3059–3069.
140. Chapman CJ, Mockridge CI, Rowe M, et al. Analysis of VH genes used by neoplastic B cells in endemic Burkitt's lymphoma shows somatic hypermutation and intracloonal heterogeneity. *Blood* 1995;85:2176–2181.
141. Chapman CJ, Zhou JX, Gregory C, et al. VH and VL gene analysis in sporadic Burkitt's lymphoma shows somatic hypermutation, intracloonal heterogeneity, and a role for antigen selection. *Blood* 1996;88:3562–3568.
142. Jain R, Roncella S, Hashimoto S, et al. A potential role for antigen selection in the clonal evolution of Burkitt's lymphoma. *J Immunol* 1994;153:45–52.
143. Tamaru J, Hummel M, Marafioti T, et al. Burkitt's lymphomas express VH genes with a moderate number of antigen-selected somatic mutations. *Am J Pathol* 1995;147:1398–1407.
144. Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt's lymphoma. *N Engl J Med* 2006;354:2431–2442.
145. Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. *N Engl J Med* 2006;354:2419–2430.
146. Dalla-Favera R, Bregni M, Erikson J, et al. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. *Proc Natl Acad Sci U S A* 1982;79:7824–7827.
147. Dalla-Favera R, Martinotti S, Gallo RC, et al. Translocation and rearrangements of the c-myc oncogene locus in human undifferentiated B-cell lymphomas. *Science* 1983;219:963–967.
148. Dalla-Favera R. Chromosomal translocations involving the c-myc oncogene in lymphoid neoplasia. In: Kirsch IR, ed. *The Causes and Consequences of Chromosomal Aberrations*. Boca Raton, FL: CRC Press; 1993: 312.
149. Taub R, Kirsch I, Morton C, et al. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. *Proc Natl Acad Sci U S A* 1982;79:7837–7841.
150. Davis M, Malcolm S, Rabbitts TH. Chromosome translocation can occur on either side of the c-myc oncogene in Burkitt lymphoma cells. *Nature* 1984;308:286–288.
151. Neri A, Barriga F, Knowles DM, et al. Different regions of the immunoglobulin heavy-chain locus are involved in chromosomal translocations in distinct pathogenetic forms of Burkitt lymphoma. *Proc Natl Acad Sci U S A* 1988;85:2748–2752.
152. Pelicci PG, Knowles DM 2nd, Magrath I, et al. Chromosomal breakpoints and structural alterations of the c-myc locus differ in endemic and sporadic forms of Burkitt lymphoma. *Proc Natl Acad Sci U S A* 1986;83:2984–2988.
153. ar-Rushdi A, Nishikura K, Erikson J, et al. Differential expression of the translocated and the untranslocated c-myc oncogene in Burkitt lymphoma. *Science* 1983;222:390–393.
154. Hayday AC, Gillies SD, Saito H, et al. Activation of a translocated human c-myc gene by an enhancer in the immunoglobulin heavy-chain locus. *Nature* 1984;307:334–340.
155. Rabbitts TH, Forster A, Baer R, et al. Transcription enhancer identified near the human C mu immunoglobulin heavy chain gene is unavailable to the translocated c-myc gene in a Burkitt lymphoma. *Nature* 1983;306:806–809.
156. Dominguez-Sola D, Victoria GD, Ying CY, et al. The proto-oncogene MYC is required for selection in the germinal center and cyclic reentry. *Nat Immunol* 2012;13:1083–1091.
157. Cesarman E, Dalla-Favera R, Bentley D, et al. Mutations in the first exon are associated with altered transcription of c-myc in Burkitt lymphoma. *Science* 1987;238:1272–1275.
158. Bhatia K, Huppi K, Spangler G, et al. Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. *Nat Genet* 1993;5:56–61.
159. Bhatia K, Spangler G, Gaiano G, et al. Mutations in the coding region of c-myc occur frequently in acquired immunodeficiency syndrome-associated lymphomas. *Blood* 1994;84:883–888.
160. Gu W, Bhatia K, Magrath IT, et al. Binding and suppression of the Myc transcriptional activation domain by p107. *Science* 1994;264:251–254.
161. Gregory MA, Hann SR. c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells. *Mol Cell Biol* 2000;20:2423–2435.
162. Hemann MT, Bric A, Teruya-Feldstein J, et al. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. *Nature* 2005;436:807–811.
163. Meyer N, Penn LZ. Reflecting on 25 years with MYC. *Nat Rev Cancer* 2008;8:976–990.
164. Dominguez-Sola D, Ying CY, Grandori C, et al. Non-transcriptional control of DNA replication by c-Myc. *Nature* 2007;448:445–451.
165. Eilers M, Eisenman RN. Myc's broad reach. *Genes Dev* 2008;22:2755–2766.
166. Amati B, Brooks MW, Levy N, et al. Oncogenic activity of the c-Myc protein requires dimerization with Max. *Cell* 1993;72:233–245.
167. Amati B, Dalton S, Brooks MW, et al. Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max. *Nature* 1992;359:423–426.
168. Blackwood EM, Eisenman RN. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. *Science* 1991;251:1211–1217.
169. Blackwood EM, Luscher B, Eisenman RN. Myc and Max associate in vivo. *Genes Dev* 1992;6:71–80.
170. Gu W, Cechova K, Tassi V, et al. Opposite regulation of gene transcription and cell proliferation by c-Myc and Max. *Proc Natl Acad Sci U S A* 1993;90:2935–2939.
171. Kretzner L, Blackwood EM, Eisenman RN. Myc and Max proteins possess distinct transcriptional activities. *Nature* 1992;359:426–429.
172. Grandori C, Cowley SM, James LP, et al. The Myc/Max/Mad network and the transcriptional control of cell behavior. *Annu Rev Cell Dev Biol* 2000;16:653–699.
173. Dang CV, O'Donnell KA, Zeller KI, et al. The c-Myc target gene network. *Semin Cancer Biol* 2006;16:253–264.
174. Felsher DW, Bishop JM. Transient excess of MYC activity can elicit genomic instability and tumorigenesis. *Proc Natl Acad Sci U S A* 1999;96:3940–3944.
175. Adams JM, Harris AW, Pinkert CA, et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. *Nature* 1985;318:533–538.
176. Kovalchuk AL, Qi CF, Torrey TA, et al. Burkitt lymphoma in the mouse. *J Exp Med* 2000;192:1183–1190.
177. Schmitz R, Young RM, Cerbelli M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. *Nature* 2012;490:116–120.
178. Lombardi L, Newcomb EW, Dalla-Favera R. Pathogenesis of Burkitt lymphoma: expression of an activated c-myc oncogene causes the tumorigenic conversion of EBV-infected human B lymphoblasts. *Cell* 1987;49:161–170.
179. Prevot S, Hamilton-Dutoit S, Audouin J, et al. Analysis of African Burkitt's and high-grade B cell non-Burkitt's lymphoma for Epstein-Barr virus genomes using in situ hybridization. *Br J Haematol* 1992;80:27–32.
180. Bornkamm GW. Epstein-Barr virus and its role in the pathogenesis of Burkitt's lymphoma: an unresolved issue. *Semin Cancer Biol* 2009;19:351–365.
181. Thorley-Lawson DA, Allday MJ. The curious case of the tumour virus: 50 years of Burkitt's lymphoma. *Nat Rev Microbiol* 2008;6:913–924.
182. Kridel R, Sehn LH, Gascoyne RD. Pathogenesis of follicular lymphoma. *J Clin Invest* 2012;122:3424–3431.
183. Montoto S, Fitzgibbon J. Transformation of indolent B-cell lymphomas. *J Clin Oncol* 2011;29:1827–1834.
184. Bakshi A, Jensen JP, Goldman P, et al. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. *Cell* 1985;41:899–906.
185. Cleary ML, Sklar J. Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. *Proc Natl Acad Sci U S A* 1985;82:7439–7443.

186. Cleary ML, Smith SD, Sklar J. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. *Cell* 1986;47:19–28.
187. Ott G, Katzenberger T, Lohr A, et al. Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. *Blood* 2002;99:3806–3812.
188. Tsujimoto Y, Finger LR, Yunis J, et al. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. *Science* 1984;226:1097–1099.
189. Cleary ML, Galili N, Sklar J. Detection of a second t(14;18) breakpoint cluster region in human follicular lymphomas. *J Exp Med* 1986;164:315–320.
190. Graninger WB, Seto M, Boutain B, et al. Expression of Bcl-2 and Bcl-2-Ig fusion transcripts in normal and neoplastic cells. *J Clin Invest* 1987;80:1512–1515.
191. Ngan BY, Chen-Levy Z, Weiss LM, et al. Expression in non-Hodgkin's lymphoma of the bcl-2 protein associated with the t(14;18) chromosomal translocation. *N Engl J Med* 1988;318:1658–1664.
192. Petrovic AS, Young RL, Hilgarth B, et al. The Ig heavy chain 3' end confers a posttranscriptional processing advantage to Bcl-2-IgH fusion RNA in t(14;18) lymphoma. *Blood* 1998;91:3952–3961.
193. Saito M, Novak U, Pivov E, et al. BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma. *Proc Natl Acad Sci U S A* 2009;106:11294–11299.
194. Buchonnet G, Jardin F, Jean N, et al. Distribution of BCL2 breakpoints in follicular lymphoma and correlation with clinical features: specific subtypes or same disease? *Leukemia* 2002;16:1852–1856.
195. Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. *Nat Genet* 2010;42:181–185.
196. Okosun J, Bodor C, Wang J, et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. *Nat Genet* 2014;46:176–181.
197. Cleary ML, Meeker TC, Levy S, et al. Clustering of extensive somatic mutations in the variable region of an immunoglobulin heavy chain gene from a human B cell lymphoma. *Cell* 1986;44:97–106.
198. Bahler DW, Levy R. Clonal evolution of a follicular lymphoma: evidence for antigen selection. *Proc Natl Acad Sci U S A* 1992;89:6770–6774.
199. Elenitoba-Johnson KS, Gascoyne RD, Lim MS, et al. Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. *Blood* 1998;91:4677–4685.
200. Yano T, Jaffe ES, Longo DL, et al. MYC rearrangements in histologically progressed follicular lymphomas. *Blood* 1992;80:758–767.
201. Ichikawa A, Hotta T, Takagi N, et al. Mutations of p53 gene and their relation to disease progression in B-cell lymphoma. *Blood* 1992;79:2701–2707.
202. O'Shea D, O'Riain C, Taylor C, et al. The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. *Blood* 2008;112:3126–3129.
203. Sander CA, Yano T, Clark HM, et al. p53 mutation is associated with progression in follicular lymphomas. *Blood* 1993;82:1994–2004.
204. Bastard C, Deweindt C, Kerckaert JP, et al. LAZ3 rearrangements in non-Hodgkin's lymphoma: correlation with histology, immunophenotype, karyotype, and clinical outcome in 217 patients. *Blood* 1994;83:2423–2427.
205. Lo Coco F, Ye BH, Lista F, et al. Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma. *Blood* 1994;83:1757–1759.
206. Otsuki T, Yano T, Clark HM, et al. Analysis of LAZ3 (BCL-6) status in B-cell non-Hodgkin's lymphomas: results of rearrangement and gene expression studies and a mutational analysis of coding region sequences. *Blood* 1995;85:2877–2884.
207. Akasaka T, Lossos IS, Levy R. BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma. *Blood* 2003;102:1443–1448.
208. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. *Blood* 1997;89:3909–2918.
209. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. *Nature* 2000;403:503–511.
210. Wright G, Tan B, Rosenwald A, et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. *Proc Natl Acad Sci U S A* 2003;100:9991–9996.
211. Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. *Blood* 2003;102:3871–3879.
212. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. *J Exp Med* 2003;198:851–862.
213. Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. *Clin Cancer Res* 2009;15:5494–5502.
214. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. *Blood* 2004;103:275–282.
215. Monti S, Savage KJ, Kutok JL, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. *Blood* 2005;105:1851–1861.
216. Lohr JG, Stojanov P, Lawrence MS, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. *Proc Natl Acad Sci U S A* 2012;109:3879–3884.
217. Pasqualucci L, Trifonov V, Fabbri G, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. *Nat Genet* 2011;43:830–837.
218. Offit K, Jhanwar S, Ebrahim SA, et al. t(3;22)(q27;q11): a novel translocation associated with diffuse non-Hodgkin's lymphoma. *Blood* 1989;74:1876–1879.
219. Iqbal J, Greiner TC, Patel K, et al. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. *Leukemia* 2007;21:2332–2343.
220. Ye BH, Chaganti S, Chang CC, et al. Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma. *Embo J* 1995;14:6209–6217.
221. Ying CY, Dominguez-Sola D, Fabi M, et al. MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma. *Nat Immunol* 2013;14:1084–1092.
222. Duan S, Cermak L, Pagan JK, et al. FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas. *Nature* 2012;481:90–93.
223. Cattoretti G, Pasqualucci L, Ballon G, et al. Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. *Cancer Cell* 2005;7:445–455.
224. Challa-Malladi M, Lieu YK, Califano O, et al. Combined genetic inactivation of β 2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. *Cancer Cell* 2011;20:728–740.
225. Iqbal J, Sanger WG, Horsman DE, et al. BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. *Am J Pathol* 2004;165:159–166.
226. Ladanyi M, Offit K, Jhanwar SC, et al. MYC rearrangement and translocations involving band 8q24 in diffuse large cell lymphomas. *Blood* 1991;77:1057–1063.
227. Pasqualucci L, Migliazza A, Basso K, et al. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. *Blood* 2003;101:2914–2123.
228. Wang X, Li Z, Naganuma A, et al. Negative autoregulation of BCL-6 is bypassed by genetic alterations in diffuse large B cell lymphomas. *Proc Natl Acad Sci U S A* 2002;99:15018–15023.
229. Pfeifer M, Grau M, Lenze D, et al. PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma. *Proc Natl Acad Sci U S A* 2013;110:12420–12425.
230. Capello D, Vitolo U, Pasqualucci L, et al. Distribution and pattern of BCL6 mutations throughout the spectrum of B-cell neoplasia. *Blood* 2000;95:651–659.
231. Migliazza A, Martinotti S, Chen W, et al. Frequent somatic hypermutation of the 5' noncoding region of the BCL6 gene in B-cell lymphoma. *Proc Natl Acad Sci U S A* 1995;92:12520–12524.
232. Saito M, Gao J, Basso K, et al. A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. *Cancer Cell* 2007;12:280–292.
233. Iqbal J, Neppalli VT, Wright G, et al. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. *J Clin Oncol* 2006;24:961–968.
234. Monni O, Joensuu H, Fransila K, et al. BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma. *Blood* 1997;90:1168–1174.
235. Lenz G, Davis RE, Ngo VN, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. *Science* 2008;319:1676–1679.
236. Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. *Nature* 2010;463:88–92.
237. Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. *Nature* 2011;470:115–119.
238. Gronbaek K, Worm J, Ralkaer E, et al. ATM mutations are associated with inactivation of the ARF-TP53 tumor suppressor pathway in diffuse large B-cell lymphoma. *Blood* 2002;100:1430–1437.
239. Angelin-Duclos C, Cattoretti G, Lin KI, et al. Commitment of B lymphocytes to a plasma cell fate is associated with Blimp-1 expression in vivo. *J Immunol* 2000;165:5462–5471.
240. Cattoretti G, Angelin-Duclos C, Shaknovich R, et al. PRDM1/Blimp-1 is expressed in human B-lymphocytes committed to the plasma cell lineage. *J Pathol* 2005;206:76–86.
241. Shapiro-Shelef M, Lin KI, McHeyzer-Williams LJ, et al. Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells. *Immunity* 2003;19:607–620.
242. Joos S, Kupper M, Ohl S, et al. Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. *Cancer Res* 2000;60:549–552.
243. Steidl C, Shah SP, Woolcock BW, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. *Nature* 2011;471:377–381.
244. Mestre C, Rubio-Moscardo F, Rosenwald A, et al. Homozygous deletion of SOCS1 in primary mediastinal B-cell lymphoma detected by CGH to BAC microarrays. *Leukemia* 2005;19:1082–1084.
245. Melzner I, Bucur AJ, Bruderlein S, et al. Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. *Blood* 2005;105:2535–2542.

246. Weniger MA, Melzner I, Menz CK, et al. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT1 δ accumulation. *Oncogene* 2006;25:2679–2684.
247. Landau DA, Carter SL, Stojanov P, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. *Cell* 2013;152:714–726.
248. Muller AM, Ihorst G, Mertelsmann R, et al. Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology. *Ann Hematol* 2005;84:1–12.
249. Bertoni F, Cazzaniga G, Bosshard G, et al. Immunoglobulin heavy chain diversity genes rearrangement pattern indicates that MALT-type gastric lymphoma B cells have undergone an antigen selection process. *Br J Haematol* 1997;97:830–836.
250. Wotherspoon AC. Gastric lymphoma of mucosa-associated lymphoid tissue and *Helicobacter pylori*. *Annu Rev Med* 1998;49:289–299.
251. Bende RJ, Aarts WM, Riedl RG, et al. Among B cell non-Hodgkin's lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity. *J Exp Med* 2005;201:1229–1241.
252. Hussell T, Isaacson PG, Crabtree JE, et al. Immunoglobulin specificity of low grade B cell gastrointestinal lymphoma of mucosa-associated lymphoid tissue (MALT) type. *Am J Pathol* 1993;142:285–292.
253. Akagi T, Motegi M, Tamura A, et al. A novel gene, MALT1 at 18q21, is involved in t(11;18)(q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue. *Oncogene* 1999;18:5785–5794.
254. Dierlamm J, Baens M, Wlodarska I, et al. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. *Blood* 1999;93:3601–3609.
255. Remstein ED, James CD, Kurtin PJ. Incidence and subtype specificity of API2-MALT1 fusion translocations in extranodal, nodal, and splenic marginal zone lymphomas. *Am J Pathol* 2000;156:1183–1188.
256. Baens M, Maes B, Steyels A, et al. The product of the t(11;18), an API2-MLT fusion, marks nearly half of gastric MALT type lymphomas without large cell proliferation. *Am J Pathol* 2000;156:1433–1439.
257. Motegi M, Yonezumi M, Suzuki H, et al. API2-MALT1 chimeric transcripts involved in mucosa-associated lymphoid tissue type lymphoma predict heterogeneous products. *Am J Pathol* 2000;156:807–812.
258. Thome M. CARMA1, BCL-10 and MALT1 in lymphocyte development and activation. *Nat Rev Immunol* 2004;4:348–359.
259. Lucas PC, Kuffa P, Gu S, et al. A dual role for the API2 moiety in API2-MALT1-dependent NF-kappaB activation: heterotypic oligomerization and TRAF2 recruitment. *Oncogene* 2007;26:5643–5654.
260. Sanchez-Izquierdo D, Buchonnet G, Siebert R, et al. MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma. *Blood* 2003;101:4539–4546.
261. Streubel B, Lamprecht A, Dierlamm J, et al. T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. *Blood* 2003;101:2335–2339.
262. Willis TC, Jadavyl DM, Du MQ, et al. Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. *Cell* 1999;96:35–45.
263. Zhang Q, Siebert R, Yan M, et al. Inactivating mutations and overexpression of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32). *Nat Genet* 1999;22:63–68.
264. Ruland J, Duncan GS, Elia A, et al. Bcl10 is a positive regulator of antigen receptor-induced activation of NF-kappaB and neural tube closure. *Cell* 2001;104:33–42.
265. Xue L, Morris SW, Orihuela C, et al. Defective development and function of Bcl10-deficient follicular, marginal zone and B1 B cells. *Nat Immunol* 2003;4:857–865.
266. Wlodarska I, Veyt E, De Paeppe P, et al. FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations. *Leukemia* 2005;19:1299–1305.
267. Streubel B, Vinatzer U, Lamprecht A, et al. T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. *Leukemia* 2005;19:652–658.
268. Hu H, Wang B, Borde M, et al. Foxp1 is an essential transcriptional regulator of B cell development. *Nat Immunol* 2006;7:819–826.
269. Wotherspoon AC, Finn TM, Isaacson PG. Trisomy 3 in low-grade B-cell lymphomas of mucosa-associated lymphoid tissue. *Blood* 1995;85:2000–2004.
270. Ott G, Kalla J, Steinhoff A, et al. Trisomy 3 is not a common feature in malignant lymphomas of mucosa-associated lymphoid tissue type. *Am J Pathol* 1998;153:689–694.
271. Du M, Peng H, Singh N, et al. The accumulation of p53 abnormalities is associated with progression of mucosa-associated lymphoid tissue lymphoma. *Blood* 1995;86:4587–4593.
272. Gaidano G, Capello D, Gloghini A, et al. Frequent mutation of bcl-6 proto-oncogene in high grade, but not low grade, MALT lymphomas of the gastrointestinal tract. *Haematologica* 1999;84:582–588.
273. Gaidano G, Volpe G, Pastore C, et al. Detection of BCL-6 rearrangements and p53 mutations in Malt-lymphomas. *Am J Hematol* 1997;56:206–213.
274. Klein U, Dalla-Favera R. New insights into the pathogenesis of chronic lymphocytic leukemia. *Semin Cancer Biol* 2010;20:377–383.
275. Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. *J Clin Invest* 1998;102:1515–1525.
276. Oscier DG, Thompsett A, Zhu D, et al. Differential rates of somatic hypermutation in V(H) genes among subsets of chronic lymphocytic leukemia defined by chromosomal abnormalities. *Blood* 1997;89:4153–4160.
277. Klein U, Tu Y, Stolovitzky GA, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. *J Exp Med* 2001;194:1625–1638.
278. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. *J Exp Med* 2001;194:1639–1647.
279. Widhopf GF 2nd, Rassenti LZ, Toy TL, et al. Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. *Blood* 2004;104:2499–2504.
280. Messmer BT, Albesiano E, Efremov DG, et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. *J Exp Med* 2004;200:519–525.
281. Tobin G, Thunberg U, Karlsson K, et al. Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia. *Blood* 2004;104:2879–2885.
282. Murray F, Darzentas N, Hadzidimitriou A, et al. Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. *Blood* 2008;111:1524–1533.
283. Stamatopoulos K, Belessi C, Moreno C, et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations. *Blood* 2007;109:259–270.
284. Tobin G, Thunberg U, Johnson A, et al. Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. *Blood* 2003;101:4952–4957.
285. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. *Blood* 1999;94:1840–1847.
286. Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. *Blood* 1999;94:1848–1854.
287. Rawstron AC, Bennett FL, O'Connor SJ, et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. *N Engl J Med* 2008;359:575–583.
288. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. *Proc Natl Acad Sci U S A* 2002;99:15524–15529.
289. Kalachikov S, Migliazza A, Cayanis E, et al. Cloning and gene mapping of the chromosome 13q14 region deleted in chronic lymphocytic leukemia. *Genomics* 1997;42:369–377.
290. Migliazza A, Bosch F, Komatsu H, et al. Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia. *Blood* 2001;97:2098–2104.
291. Klein U, Lia M, Crespo M, et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. *Cancer Cell* 2010;17:28–40.
292. Anastasi J, Le Beau MM, Vardiman JW, et al. Detection of trisomy 12 in chronic lymphocytic leukemia by fluorescence in situ hybridization to interphase cells: a simple and sensitive method. *Blood* 1992;79:796–1801.
293. Hjalmar V, Kimby E, Matutes E, et al. Trisomy 12 and lymphoplasmacytoid lymphocytes in chronic leukemic B-cell disorders. *Haematologica* 1998;83:602–609.
294. Juliusson G, Oscier DG, Fitchett M, et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. *N Engl J Med* 1990;323:720–724.
295. Bullrich F, Rasio D, Kitada S, et al. ATM mutations in B-cell chronic lymphocytic leukemia. *Cancer Res* 1999;59:24–27.
296. Stankovic T, Weber P, Stewart G, et al. Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia. *Lancet* 1999;353:26–29.
297. Starostik P, Manshour T, O'Brien S, et al. Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia. *Cancer Res* 1998;58:4552–4557.
298. Rossi D, Fangazio M, Rasi S, et al. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. *Blood* 2012;119:2854–2862.
299. Caidano G, Foa R, Dalla-Favera R. Molecular pathogenesis of chronic lymphocytic leukemia. *J Clin Invest* 2012;122:3432–3438.
300. Fabbri G, Rasi S, Rossi D, et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. *J Exp Med* 2011;208:1389–1401.
301. Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. *Nature* 2011;475:101–105.
302. Quesada V, Conde L, Villamor N, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. *Nat Genet* 2012;44:47–52.
303. Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. *N Engl J Med* 2011;365:2497–2506.

304. Rossi D, Brusca G, Spina V, et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. *Blood* 2011;118:6904–6908.
305. Carbone A, Ghossein A. AIDS-related lymphomas: from pathogenesis to pathology. *Br J Haematol* 2005;130:662–670.
306. Knowles DM. Etiology and pathogenesis of AIDS-related non-Hodgkin's lymphoma. *Hematol Oncol Clin North Am* 2003;17:785–820.
307. Gaidano G, Capello D, Carbone A. The molecular basis of acquired immunodeficiency syndrome-related lymphomagenesis. *Semin Oncol* 2000;27:431–441.
308. Carbone A, Gaidano G. HHV-8-positive body-cavity-based lymphoma: a novel lymphoma entity. *Br J Haematol* 1997;97:515–522.
309. Gaidano G, Carbone A. Primary effusion lymphoma: a liquid phase lymphoma of fluid-filled body cavities. *Adv Cancer Res* 2001;80:115–146.
310. Gaidano G, Ghossein A, Gattei V, et al. Association of Kaposi's sarcoma-associated herpesvirus-positive primary effusion lymphoma with expression of the CD138/syndecan-1 antigen. *Blood* 1997;90:4894–4900.
311. Carbone A, Gaidano G, Ghossein A, et al. BCL-6 protein expression in AIDS-related non-Hodgkin's lymphomas: inverse relationship with Epstein-Barr virus-encoded latent membrane protein-1 expression. *Am J Pathol* 1997;150:155–165.
312. Carbone A, Gaidano G, Ghossein A, et al. Differential expression of BCL-6, CD138/syndecan-1, and Epstein-Barr virus-encoded latent membrane protein-1 identifies distinct histogenetic subsets of acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. *Blood* 1998;91:747–755.
313. Riboldi P, Gaidano G, Schettino EW, et al. Two acquired immunodeficiency syndrome-associated Burkitt's lymphomas produce specific anti-IgM cold agglutinins using somatically mutated VH4-21 segments. *Blood* 1994;83:2952–2961.
314. Gaidano G, Lo Coco F, Ye BH, et al. Rearrangements of the BCL-6 gene in acquired immunodeficiency syndrome-associated non-Hodgkin's lymphoma: association with diffuse large-cell subtype. *Blood* 1994;84:397–402.
315. Gaidano G, Carbone A, Pastore C, et al. Frequent mutation of the 5' non-coding region of the BCL-6 gene in acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. *Blood* 1997;89:3755–3762.
316. MacMahon EM, Glass JD, Hayward SD, et al. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. *Lancet* 1991;338:969–973.
317. Larocca LM, Capello D, Rinelli A, et al. The molecular and phenotypic profile of primary central nervous system lymphoma identifies distinct categories of the disease and is consistent with histogenetic derivation from germinal center-related B cells. *Blood* 1998;92:1011–1019.
318. Montesinos-Rongen M, Godlewski E, Brunn A, et al. Mutations of CARD11 but not TNFAIP3 may activate the NF-kappaB pathway in primary CNS lymphoma. *Acta Neuropathol* 2010;120:529–535.
319. Antinori A, Larocca LM, Fassone L, et al. HHV-8/KSHV is not associated with AIDS-related primary central nervous system lymphoma. *Brain Pathol* 1999;9:199–208.
320. Gaidano G, Capello D, Pastore C, et al. Analysis of human herpesvirus type 8 infection in AIDS-related and AIDS-unrelated primary central nervous system lymphoma. *J Infect Dis* 1997;175:1193–1197.
321. de Leval L, Bisig B, Thielen C, et al. Molecular classification of T-cell lymphomas. *Crit Rev Oncol Hematol* 2009;72:125–143.
322. Taylor GP. The epidemiology of HTLV-I in Europe. *J Acquir Immune Defic Syndr Hum Retrovirology* 1996;13:S8–14.
323. Tsukasaki K, Tsumahira H, Yamamura M, et al. Integration patterns of HTLV-I provirus in relation to the clinical course of ATL: frequent clonal change at crisis from indolent disease. *Blood* 1997;89:948–956.
324. Takatsuki K, Matsuoka M, Yamaguchi K. Adult T-cell leukemia in Japan. *J Acquir Immune Defic Syndr Hum Retrovirology* 1996;13:S15–S19.
325. Uittenbogaard MN, Giebler HA, Reisman D, et al. Transcriptional repression of p53 by human T-cell leukemia virus type I Tax protein. *J Biol Chem* 1995;270:28503–28506.
326. Cesarman E, Chadburn A, Inghirami G, et al. Structural and functional analysis of oncogenes and tumor suppressor genes in adult T-cell leukemia/lymphoma shows frequent p53 mutations. *Blood* 1992;80:3205–3216.
327. Sakashita A, Hattori T, Miller CW, et al. Mutations of the p53 gene in adult T-cell leukemia. *Blood* 1992;79:477–480.
328. Gaulard P, Bourquelot P, Kanavaros P, et al. Expression of the alpha/beta and gamma/delta T-cell receptors in 57 cases of peripheral T-cell lymphomas. Identification of a subset of gamma/delta T-cell lymphomas. *Am J Pathol* 1990;137:617–628.
329. de Leval L, Rickman DS, Thielen C, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. *Blood* 2007;109:4952–4963.
330. Martin-Subero JI, Wlodarska I, Bastard C, et al. Chromosomal rearrangements involving the BCL3 locus are recurrent in classical Hodgkin and peripheral T-cell lymphoma. *Blood* 2006;108:401–402.
331. Almire C, Bertrand P, Ruminy P, et al. PVRL2 is translocated to the TRA@ locus in t(14;19)(q11;q13)-positive peripheral T-cell lymphomas. *Genes Chromosomes Cancer* 2007;46:1011–1018.
332. Feldman AL, Law M, Remstein ED, et al. Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas. *Leukemia* 2009;23:574–580.
333. Palomero T, Couronne L, Khiabani H, et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. *Nat Genet* 2014;46:166–170.
334. Sakata-Yanagimoto M, Enami T, Yoshida K, et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. *Nat Genet* 2014;46:171–175.
335. Panwalkar AW, Armitage JO. T-cell/NK-cell lymphomas: a review. *Cancer Lett* 2007;253:1–13.
336. Piccaluga PP, Agostinelli C, Califano A, et al. Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation. *Cancer Res* 2007;67:10703–10710.
337. Grogg KL, Attygalle AD, Macon WR, et al. Angioimmunoblastic T-cell lymphoma: a neoplasm of germinal-center T-helper cells? *Blood* 2005;106:1501–1502.
338. Chang CC, Zhang J, Lombardi L, et al. Rearranged NFKB-2 genes in lymphoid neoplasms code for constitutively active nuclear transactivators. *Mol Cell Biol* 1995;15:5180–5187.
339. Neri A, Chang CC, Lombardi L, et al. B cell lymphoma-associated chromosomal translocation involves candidate oncogene *lyt-10*, homologous to NF-kappa B p50. *Cell* 1991;67:1075–1087.
340. Fornari A, Piva R, Chiarle R, et al. Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma? *Hematol Oncol* 2009;27:161–170.
341. Lamant L, de Reynies A, Duplantier MM, et al. Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. *Blood* 2007;109:2156–2164.
342. Gascoyne RD, Aoun P, Wu D, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. *Blood* 1999;93:3913–3921.
343. Savage KJ, Harris NL, Vose JM, et al. ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. *Blood* 2008;111:5496–5504.
344. Shiota M, Nakamura S, Ichinohasama R, et al. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. *Blood* 1995;86:1954–1960.
345. Piva R, Agnelli L, Pellegrino E, et al. Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms. *J Clin Oncol* 2010;28:1583–1590.
346. Chiarle R, Voena C, Ambrogio C, et al. The anaplastic lymphoma kinase in the pathogenesis of cancer. *Nat Rev Cancer* 2008;8:11–23.
347. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. *Science* 1994;263:1281–1284.
348. Kasprzycka M, Marzec M, Liu X, et al. Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3. *Proc Natl Acad Sci U S A* 2006;103:9964–9969.
349. Marzec M, Zhang Q, Goradia A, et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). *Proc Natl Acad Sci U S A* 2008;105:20852–20857.
350. Zhang Q, Wang HY, Liu X, et al. STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression. *Nat Med* 2007;13:1341–1348.
351. Bai RY, Ouyang T, Miething C, et al. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. *Blood* 2000;96:4319–4327.
352. Chiarle R, Gong JZ, Guasparri I, et al. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. *Blood* 2003;101:1919–1927.
353. Kuefer MU, Look AT, Pulford K, et al. Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice. *Blood* 1997;90:2901–2910.
354. Lange K, Ueckert W, Blankenstein T, et al. Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice. *Oncogene* 2003;22:517–527.
355. Hernandez L, Bea S, Bellosillo B, et al. Diversity of genomic breakpoints in TFC-ALK translocations in anaplastic large cell lymphomas: identification of a new TFC-ALK(XL) chimeric gene with transforming activity. *Am J Pathol* 2002;160:1487–1494.
356. Colleoni GW, Bridge JA, Garicochea B, et al. ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35). *Am J Pathol* 2000;156:781–789.
357. Ma Z, Cools J, Marynen P, et al. Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis. *Blood* 2000;95:2144–2149.
358. Feldman AL, Vasmatzis G, Asmann YW, et al. Novel TRAF1-ALK fusion identified by deep RNA sequencing of anaplastic large cell lymphoma. *Genes Chromosomes Cancer* 2013;52:1097–1102.
359. Kuppers R. The biology of Hodgkin's lymphoma. *Nat Rev Cancer* 2009;9:15–27.

360. Schwering I, Brauning A, Klein U, et al. Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. *Blood* 2003;101:1505–1512.
361. Re D, Muschen M, Ahmadi T, et al. Oct-2 and Bob-1 deficiency in Hodgkin and Reed Sternberg cells. *Cancer Res* 2001;61:2080–2084.
362. Stein H, Marafioti T, Foss HD, et al. Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription. *Blood* 2001;97:496–501.
363. Küppers R, Rajewsky K, Zhao M, et al. Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. *Proc Natl Acad Sci U S A* 1994;91:10962–10966.
364. Kanzler H, Kuppers R, Hansmann ML, et al. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. *J Exp Med* 1996;184:1495–1505.
365. Martin-Subero JI, Gesk S, Harder L, et al. Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. *Blood* 2002;99:1474–1477.
366. Barth TF, Martin-Subero JI, Joos S, et al. Gains of 2p involving the REL locus correlate with nuclear c-Rel protein accumulation in neoplastic cells of classical Hodgkin lymphoma. *Blood* 2003;101:3681–3686.
367. Jungnickel B, Staratschek-Jox A, Brauning A, et al. Clonal deleterious mutations in the I kappa B alpha gene in the malignant cells in Hodgkin's lymphoma. *J Exp Med* 2000;191:395–402.
368. Emmerich F, Meiser M, Hummel M, et al. Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. *Blood* 1999;94:3129–3134.
369. Schmitz R, Stanelle J, Hansmann ML, et al. Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma. *Annu Rev Pathol* 2009;4:151–174.
370. Wlodarska I, Nooyen P, Maes B, et al. Frequent occurrence of BCL6 rearrangements in nodular lymphocyte predominance Hodgkin lymphoma but not in classical Hodgkin lymphoma. *Blood* 2003;101:706–710.
371. Martin-Subero JI, Klapper W, Sotnikova A, et al. Chromosomal breakpoints affecting immunoglobulin loci are recurrent in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma. *Cancer Res* 2006;66:10332–10338.